A wide variety of symptoms and organs are involved in SARS-CoV-2 infection. This phenomenon could be explained by the distribution of the virus's gateway receptor, which is found in tissues throughout the body. Characterization of angiotensin-converting enzyme 2 (ACE2) expression is detailed in a recent Cellular and Molecular Neurobiology article.  

Human genetic variation may alter the interactions of drugs being used to treat patients with COVID-19 symptoms, resulting in a range of clinical responses -- from no effect to high toxicity in some patients, according to a study published in Nature Genomic Medicine on August 18.  

Provention Bio has begun a phase IIb study of Prv-015, an anti-interleukin-15 monoclonal antibody (mAb), in adult patients with nonresponsive celiac disease. The drug is being developed in collaboration with Amgen as potentially the first approved therapeutic for celiac disease.  

Scientists have developed a new next-generation sequencing technique using molecular barcodes that can accurately detect a single genetic mutation in a pool of 10,000 cells. The researchers applied the approach to CRISPR-Cas9 genome editing to search for undesirable mutations caused by the platform. The research and methods were published in Genome Biology on August 24.  

Human genetic variation may alter the interactions of drugs being used to treat patients with COVID-19 symptoms, resulting in a range of clinical responses -- from no effect to high toxicity in some patients, according to a study published in Nature Genomic Medicine on August 18.  

A new mouse-adapted SARS-CoV-2 model developed with engineered virus can help accelerate vaccine and therapeutic candidates to clinical trials. The results of the preclinical studies were published in Nature on August 27.  

The Commonwealth of Pennsylvania has awarded Thomas Jefferson University a grant for the development of CoraVax, a novel COVID-19 vaccine.  

Moderna is in discussion with the Ministry of Health, Labour, and Welfare of Japan to potentially purchase 40 million or more doses of its messenger RNA vaccine candidate against COVID-19 to support Japan's efforts to secure vaccines as soon as possible.  

Provention Bio has begun a phase IIb study of Prv-015, an anti-interleukin-15 monoclonal antibody (mAb), in adult patients with nonresponsive celiac disease. The drug is being developed in collaboration with Amgen as potentially the first approved therapeutic for celiac disease.  

Biopharmaceutical firm Verndari has secured funding from the Biomedical Advanced Research and Development Authority (BARDA), a U.S. federal health agency, to support development of its VaxiPatch microneedle dermal patch vaccine technology.  

The U.S. National Cancer Institute (NCI) has partnered with Cancer Research U.K. to fund Cancer Grand Challenges, an international initiative to support new ideas for cancer research.  

A wide variety of symptoms and organs are involved in SARS-CoV-2 infection. This phenomenon could be explained by the distribution of the virus's gateway receptor, which is found in tissues throughout the body. Characterization of angiotensin-converting enzyme 2 (ACE2) expression is detailed in a recent Cellular and Molecular Neurobiology article.